Skip to the main content

Creative Touch Permanent Makeup and Aesthetics

Thymic stromal lymphopoietin

Protein Cytokine

Thymic stromal lymphopoietin (TSLP) is the alarmin that converts barrier damage into immune disease. Produced by when the is disrupted, when is activated by excess proteases, or when is triggered by microbial stimuli, it functions as the ’s distress signal to the immune system – but the signal it sends is not a generalised alert. It is a highly specific instruction to polarise toward Th2, and it issues that instruction simultaneously to multiple immune cell types through mechanisms that bypass IL-12-driven Th1 regulation entirely.

The downstream consequences are the immune architecture of atopic disease: , , and IL-5 production, IgE class switching, priming, eosinophil recruitment, and – through the TSLP/TRPV3/sensory neuron axis – the neurogenic itch that sustains the scratch-induced barrier damage that generates more TSLP. Within this knowledge base, TSLP is the molecular pivot point that connects the barrier entities ( , , , , ) to the immune entities (NF-κB, NLRP3, , ) to the clinical condition entities ( , , ). Every upstream barrier or protease entity that generates TSLP is contributing to the Th2 polarisation and itch amplification that TSLP drives. Every downstream treatment that reduces the Th2 environment – CAP, , dupilumab – is, among other mechanisms, reducing the consequences of TSLP signalling.

In 2001, TSLP was identified as an epithelial cytokine with the unusual capacity to activate myeloid dendritic cells in a way that drove Th2 differentiation without producing IL-12. That IL-12 absence turned out to be as important as anything TSLP actively does. IL-12 is the signal that drives Th1 polarisation, the immune architecture of anti-pathogen and antitumour responses. TSLP-activated dendritic cells mature fully – upregulate all major costimulatory molecules, present antigen effectively, recruit T cells – but without the IL-12 that would direct those T cells toward a Th1 response. Into that IL-12 vacuum, TSLP’s second instruction – OX40L upregulation on dendritic cells – drives naïve CD4+ T cells toward inflammatory Th2 differentiation. The result is an immune response to a barrier breach that is maximally primed for allergy and atopy, and minimally equipped for pathogen clearance. [6]

That is what produces, at the molecular level, when TSLP is the signal carrying the damage report.

Two isoforms: constitutive baseline and inducible alarm

TSLP exists in two isoforms with distinct expression patterns and functional roles – a distinction largely absent from clinical-facing content but mechanistically important. [1]

Short-form TSLP is constitutively expressed at low levels by keratinocytes in healthy skin. It contributes to baseline homeostatic immune regulation – maintaining commensal tolerance and supporting normal T regulatory cell function in the skin-draining lymph nodes. It is not pro-inflammatory at homeostatic concentrations. Its presence is normal and functionally necessary. [1]

Long-form TSLP is the inducible isoform – generated from an alternative promoter upstream of the short-form promoter, driven by NF-κB, AP-1, and IRF3 activation in keratinocytes in response to: PAR2 activation by KLK5/KLK14 excess, mechanical skin damage (scratching, tape stripping, needle trauma), TLR ligand stimulation by microbial products, IL-1 and (inflammatory cytokines), protease-containing allergens (Der p1 from house dust mite, cockroach allergen CR1), and staphylococcal toxins ( α-toxin, Protein A). [12]

Long-form TSLP is the pathological driver. The short-form is the background hum. When practitioners, researchers, or dermatologists refer to “TSLP elevation” in skin disease – serum TSLP correlating with disease severity, TSLP overexpression in AD lesional skin, tezepelumab blocking TSLP in asthma and AD – they are referring to long-form TSLP generated by the inducible pathway. The homeostatic short-form isoform is not typically measured or targeted. This distinction matters because it positions TSLP not as an inherently dangerous molecule but as an inducible danger signal that is only pathological when the stimuli generating it are chronic and dysregulated. [1]

TSLP as a reporter of keratinocyte differentiation failure

One of the most useful framings in the TSLP literature comes from experiments with Notch-signalling-deficient keratinocytes, which demonstrated that TSLP overproduction is a direct readout of failure – specifically, of the failure to execute the terminal differentiation programme that produces a competent stratum corneum. [8]

When keratinocytes cannot differentiate normally – whether through FLG null mutations, IL-4/IL-13-driven FLG suppression, KLK5-mediated filaggrin degradation, or SPINK5 polymorphism-driven LEKTI insufficiency – TSLP is produced not as an incidental inflammatory response but as a direct molecular consequence of the differentiation programme failing to complete. The keratinocyte, unable to form the it should be producing, instead signals its failure to the immune system. TSLP is the distress call. The immune response TSLP generates – Th2 polarisation, IL-4/IL-13 production, filaggrin suppression – then compounds the original differentiation failure in a self-sustaining loop. [8]

This framing positions TSLP as a feedback mechanism: barrier failure → TSLP → Th2 → IL-4/IL-13 → more filaggrin suppression → more barrier failure → more TSLP. The loop closes around the differentiation failure that started it.

TSLP’s cellular targets – the full network

TSLP acts on a wider range of immune cells than any other epithelial cytokine, which is why its effects are systemic rather than locally contained. [2]

Myeloid dendritic cells (mDCs). The primary and most characterised target. TSLP binds the TSLP receptor (TSLPR, a heterodimer of IL-7Rα and CRLF2) on mDCs and drives: full maturation without IL-12 production; strong OX40L upregulation; TARC (CCL17) and MDC (CCL22) production to recruit Th2 cells into the activated tissue; and the priming state that instructs naïve CD4+ T cells to differentiate into inflammatory Th2 cells producing IL-4, IL-5, IL-13, and TNF-α, whilst specifically suppressing IL-10 production. The OX40/OX40L interaction at the DC-T cell synapse is the specific molecular switch driving Th2 lineage commitment – TSLP drives OX40L expression on the DC, OX40L on the DC activates OX40 on the naïve T cell, OX40 signalling induces NFATc1, NFATc1 triggers IL-4 production, and IL-4 drives GATA-3 transcription that locks in the Th2 fate. The cascade from TSLP to committed Th2 cell involves four sequential molecular steps. [3]

Mast cells. TSLP directly primes mast cells for enhanced IgE-mediated degranulation – lowering the activation threshold for histamine, prostaglandin, and tryptase release. In TSLP-primed mast cells, IgE cross-linking produces substantially higher mediator release than in un-primed cells. Mast cell tryptase released during degranulation then activates PAR2 on keratinocytes and sensory neurons – closing the mast cell/TSLP/PAR2 positive feedback loop described in the PAR2 entity. [12]

ILC2s (Innate Lymphoid Cell type 2). TSLP is a primary activating signal for ILC2s – the innate immune cells that produce IL-4, IL-5, and IL-13 without requiring antigen-specific T cell activation. ILC2 activation by TSLP provides an immediate, antigen-independent source of Th2 cytokines – meaning Th2 polarisation begins before adaptive immune sensitisation has occurred. ILC2s bridge the gap between the TSLP danger signal and the fully established Th2 adaptive response, sustaining Th2 cytokine production continuously rather than requiring each allergen exposure to separately activate T cells. [7]

Basophils. TSLP activates basophils to produce IL-4 and IL-13 directly, and promotes their recruitment from bone marrow to skin-draining lymph nodes – where they act as accessory cells for Th2 differentiation, providing the IL-4 that antigen-presenting cells need to sustain Th2 priming in the absence of ILC2 or mast cell support. [2]

CD4+ T cells (direct effects). Beyond DC-mediated indirect Th2 induction, TSLP signals directly through TSLPR on CD4+ T cells – promoting Th2 expansion and suppressing the regulatory T cell populations that would otherwise contain the Th2 response. TSLP can also act on CD8+ T cells, promoting their Th2-cytokine-producing, less cytotoxic phenotype. [12]

Sensory neurons – the itch axis. TSLP activates TRPA1 and TRPV1 on cutaneous sensory C-fibres directly through TSLPR expressed on those fibres, driving immediate influx, action potential generation, and central itch signalling without requiring any immune cell intermediary. This is a direct epithelial cell-to-neuron TSLP signal that operates at the speed of neural depolarisation – not the hours-timescale of cytokine-mediated immune activation. [5]

A parallel route through TRPV4 has been specifically characterised for dry skin-induced pruritus: TSLP produced by mechanically-stimulated (scratching, drying) keratinocytes activates TRPV4 on sensory neurons, generating the itch associated with dry, barrier-disrupted skin independent of the immune-mediated Th2 cascade. TRPV4-mediated itch is therefore the immediate neurological consequence of barrier disruption via TSLP, while the TRPV3/TRPA1-mediated itch is the sustained consequence of PAR2-driven TSLP production in the established Th2-inflammatory context. [5]

TSLP and the atopic march

The atopic march – the progression from infantile AD to childhood food allergy to adolescent asthma and allergic rhinitis – is not a sequential coincidence. TSLP is the mechanistic driver that converts a skin barrier defect into systemic allergen sensitisation and then into extra-cutaneous atopic disease.

The sequence is: skin barrier defect → allergen penetration and TSLP production → TSLP → DC/ILC2/mast cell activation → Th2 immune polarisation in skin → IgE production and systemic allergen sensitisation via the skin-draining lymph nodes → subsequent allergen encounter at gut or airway epithelium in an already-Th2-skewed immune system → food allergy, asthma. [11]

A 2026 Allergy editorial on elevated serum TSLP in the context of the Epithelial Barrier Theory expanded this further: serum TSLP levels correlate with the full spectrum of atopic comorbidities across tissues – AD, asthma, eosinophilic oesophagitis, food allergy – consistent with the hypothesis that chronic barrier disruption at the skin, gut, and airway generates a sustained TSLP signal that is educating the immune system toward Th2 at every tissue interface simultaneously. TSLP is not simply the alarmin of skin disease. It is the molecular mechanism by which the skin becomes the first organ in a cascade of atopic sensitisation – which is why early aggressive skin barrier management in infants at high AD risk is not merely treating a skin condition but potentially interrupting the atopic march before it progresses to systemic allergic disease. [11]

TSLP in specific skin conditions

Atopic dermatitis. TSLP expression is elevated throughout AD lesional skin, highest in the granular layer keratinocytes, and correlates directly with SCORAD severity, stratum corneum hydration scores, and serum IgE levels. Its overexpression is driven simultaneously by: KLK5-mediated PAR2 activation, filaggrin deficiency creating the barrier breach that allows allergen/protease penetration, IL-4/IL-13 from the Th2 environment sustaining NF-κB activation, and S. aureus toxins including α-toxin and Protein A directly activating keratinocyte NF-κB. The TSLP elevation in AD is not the initiating event – it is a sustained amplifier of an inflammatory loop that was started by barrier failure and microbial . [9]

Rosacea. TSLP contributes to rosacea pathology primarily through the mast cell sensitisation route. LL-37-driven mast cell degranulation produces tryptase → PAR2 → TSLP production – and TSLP-primed mast cells in rosacea-affected skin respond to the same triggers (UV, heat, Demodex protease activity) with substantially amplified degranulation compared to un-primed cells. TRPV1 expression – the sensory receptor activated downstream of TSLP on sensory neurons – is significantly elevated in rosacea skin with erythema telangiectasia compared to healthy controls. This positions TSLP as a mast cell sensitisation mechanism in rosacea – not the primary driver, but a sustained amplifier of mast cell reactivity that lowers the trigger threshold over time, explaining why rosacea triggers produce increasingly severe responses as the condition progresses. [10]

Acne vulgaris. PAR2 activation in acne keratinocytes and by proteases drives TSLP production as part of the NF-κB-mediated innate immune response. TSLP contributes to the recruitment of dendritic cells and mast cells to the inflamed follicular environment – the cellular infiltrate that sustains the perifollicular inflammatory response beyond the initial innate activation. The Th2-skewing potential of TSLP in the acne follicular environment may partially explain the mixed Th2/Th17 inflammatory cytokine picture sometimes seen in more persistent adult acne presentations. [4]

. TSLP plays a complex, partially paradoxical role. It is elevated in psoriatic plaques and drives aspects of the innate inflammatory response. However, the dominant psoriatic immune response is Th17 rather than Th2 – and TSLP’s Th2-driving activity partially counteracts the Th17 skewing through the same IL-12 suppression mechanism that promotes Th2 in AD. Some psoriasis patients show atopic features (elevated IgE, Th2 cytokines co-existing with Th17) – and TSLP elevation in psoriatic tissue may be partly responsible for this mixed phenotype in susceptible individuals. [9]

TSLP and tezepelumab – the therapeutic validation

Tezepelumab (Tezspire, AstraZeneca/Amgen) – a fully human anti-TSLP monoclonal antibody blocking TSLP from binding its receptor – received FDA approval for severe asthma in 2021, NICE approval for NHS use in the UK in April 2023 (NICE TA880), and US FDA approval for chronic rhinosinusitis with nasal polyps in October 2025 – with active clinical investigation ongoing for AD and eosinophilic oesophagitis. Notably, NICE approved it without a biomarker threshold requirement – available regardless of eosinophil count – a clinical distinction unique among the six NHS-approved severe asthma biologics and directly consistent with its upstream TSLP mechanism. Its efficacy across multiple Th2-driven conditions at different tissue sites is the most direct clinical validation of TSLP’s central role in the atopic cascade. [7]

In severe asthma, tezepelumab reduces exacerbations by 70% regardless of blood eosinophil count – which means it is working upstream of the eosinophil-producing IL-5 signal, at the TSLP level that drives the entire Th2 programme, rather than targeting any single downstream cytokine. This is precisely what its mechanistic position predicts: blocking TSLP simultaneously reduces ILC2 activation, mast cell priming, DC-mediated Th2 induction, and basophil recruitment – addressing the entire Th2 architecture rather than a single output node. [7]

For our Aesthetics knowledge base, tezepelumab is the pharmaceutical evidence that TSLP is the correct therapeutic target at the innate-to-adaptive immune bridge. Dupilumab blocks the IL-4/IL-13 outputs of the Th2 response; tezepelumab blocks the TSLP input that drives those outputs. The distinction is clinically meaningful: dupilumab controls established Th2 disease; tezepelumab theoretically prevents it from being initiated.

Published

Clinical Application

TSLP does not have a direct clinical intervention within the aesthetics and homecare scope – no licensed topical product targets TSLP expression. But its biology is the explanatory backbone for why every upstream barrier intervention has downstream immune consequences, and why some client presentations behave the way they do despite technically adequate topical management.

TSLP as the mechanism behind the atopic march – the systemic stakes of AD

The atopic march data gives TSLP biology its most direct clinical application: understanding that AD is not a self-contained skin condition but a TSLP-driven systemic sensitisation process changes both the urgency and the framing of barrier management conversations. Early, consistent, barrier-focused management reduces TSLP production that is driving systemic Th2 sensitisation – potentially interrupting the progression to food allergy and asthma before those conditions establish. [12]

The clinical value of this framework is not that it expands scope – it does not. It is that it explains to adult clients why their AD history matters beyond their skin’s current appearance; why a client whose child has significant AD should understand the systemic implications when speaking to their GP or dermatologist; and why the barrier management programme being recommended in the aesthetics setting is addressing something with immune consequences that extend well beyond cosmetic outcome. TSLP is the mechanism that makes that case. A practitioner who can articulate it accurately is providing a quality of clinical context that most consultations – GP or otherwise – do not offer. [11]

The TSLP/barrier loop – why topical treatment without barrier restoration is incomplete

Every clinical intervention that fails to address the underlying barrier deficit is leaving the TSLP production stimulus in place. A client using or biologic therapy prescribed by their dermatologist to suppress the inflammatory consequences of TSLP signalling – without repairing the filaggrin-depleted, ceramide-deficient, pH-disrupted barrier that is generating TSLP continuously – is managing downstream effects while the upstream stimulus continues. The barrier generates TSLP. TSLP generates Th2 polarisation. Th2 polarisation suppresses filaggrin. The loop continues at every treatment gap. [8]

The treatment architecture that actually interrupts this loop requires simultaneous action at multiple levels:

  • Barrier lipid restoration – ceramides, , ratios, repletion – reducing and allergen/protease penetration that generates the NF-κB signal driving TSLP
  • KLK5/acid mantle management – reducing PAR2-driven TSLP production through the protease route by maintaining the pH that restricts KLK5 to the superficial corneum
  • sufficiency – restoring hBD-2/hBD-3 and LL-37 expression reduces microbial stimuli (particularly S. aureus colonisation driving α-toxin/Protein A-mediated TSLP induction) and reduces the barrier fragility that generates mechanical TSLP stimuli [12]
  • CAP – reducing IL-4/IL-13 through cytokine suppression removes the Th2-driven NF-κB activation that was sustaining TSLP production in the keratinocyte, and directly reduces the KLK5-dysregulation mechanism by improving the epidermal environment

No single intervention closes the loop. The combination does.

TSLP and the mast cell sensitisation trajectory in rosacea

The mast cell priming function of TSLP explains a clinical observation in rosacea that often surprises practitioners: clients who have had rosacea for longer, or whose rosacea has been poorly controlled, tend to react more severely to triggers than clients with early-stage disease. This is not simply disease progression in a generic sense. It is a mechanistically specific consequence of prolonged TSLP-driven mast cell sensitisation – the primed mast cell population responding to stimuli that would have been sub-threshold before the sensitisation was established. [9]

Every LL-37 excess episode generates TSLP, which primes the next generation of mast cells to respond more vigorously to the next trigger. Managing rosacea is therefore a race between treatment-driven de-sensitisation and continued trigger-driven sensitisation. Consistent trigger avoidance, acid mantle maintenance, and professional treatments reducing the existing inflammatory environment are all working toward a de-sensitisation goal – not just symptom suppression. Explaining this trajectory to rosacea clients is how you communicate why consistent management is more effective than reactive treatment of individual flares.

Biologic therapy and the barrier deficit – the complementary role

Dupilumab and tezepelumab are specialist-prescribed treatments outside aesthetics scope – but clients already on these biologics from their dermatologist will arrive at the clinic, and understanding their mechanisms enables intelligent complementary management. The distinction is mechanistically clean: dupilumab blocks IL-4Rα, interrupting the IL-4 and IL-13 signalling that suppresses filaggrin and drives Th2 effector function; tezepelumab blocks TSLP upstream, preventing the Th2 polarisation instruction from being issued in the first place. [7]

Both leave the barrier deficit entirely in place – neither replaces the filaggrin that FLG mutations reduce, the ceramides the Th2 environment depletes, or the acid mantle that barrier dysfunction alkalises. This is the precise clinical role for the aesthetics and homecare programme alongside biologic therapy: the dermatologist addresses the immune architecture; the barrier restoration programme addresses the structural deficit that no biologic touches. These are not competing approaches. They are addressing different parts of the same problem – and a client on dupilumab who understands why their practitioner is still emphasising barrier lipids, pH management, and vitamin D is a client who maintains their homecare programme rather than assuming the injection does it all.

CAP and TSLP – the mechanism of relevance

CAP’s documented suppression of IL-4 and IL-13 in atopic presentations removes the Th2-driven NF-κB activation that sustains long-form TSLP production in keratinocytes. This is a legitimate CAP mechanism that reduces TSLP production from the established-inflammation route – not the PAR2/KLK5 protease route (which requires acid mantle management and barrier restoration to address), but the inflammatory amplification route that keeps TSLP elevated long after the initial barrier breach that started it.

For clients with established AD where the inflammation is self-sustaining through the TSLP → Th2 → IL-4/IL-13 → TSLP loop, CAP interrupts the loop from inside – reducing the cytokine environment that is driving continued TSLP expression, not just treating the symptoms of TSLP-driven inflammation. The mechanism is specific. That specificity is worth communicating in the clinical rationale for CAP in AD presentations.

Clinical Pearl TSLP is the molecular explanation for why some clients’ skin behaves systemically – why a rosacea client also has asthma, why an AD client has food allergies, why an adult with persistent adult acne also has atopic features that nobody has connected to the skin condition. The Epithelial Barrier Theory – that chronic barrier disruption at skin, gut, and airway generates sustained TSLP signalling that educates the immune system toward Th2 at every tissue surface simultaneously – is the current leading framework for understanding why allergic and atopic conditions cluster in the same individuals. It is not a framework that most clients have been offered, and it is not one that most GPs have time to explain. An aesthetics practitioner who understands it can give a client with AD and asthma a coherent, accurate explanation of why those conditions share the same underlying barrier and immune architecture – and why the barrier programme they are following is addressing more than surface appearance. That understanding changes what the client thinks they are doing when they apply their barrier cream. Compliance with a barrier restoration programme feels different when it is framed as managing the upstream mechanism of a systemic immune response rather than moisturising dry skin.

References

  1. Döhner K, John OP, Werfel T (2026). Thymic stromal lymphopoietin (TSLP) – pro-inflammatory cytokine and antimicrobial peptide. Biochim Biophys Acta Mol Cell Res, 1873(4), 120127 .

  2. Ebina-Shibuya R, Leonard WJ (2023). Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol, 23(1), 24-37 .

  3. Ito T, Liu YJ, Arima K (2012). Cellular and molecular mechanisms of TSLP function in human allergic disorders—TSLP programs the “Th2 code” in dendritic cells. Allergol Int, 61(1), 35-43 .

  4. Jin Z, Song Y, He L (2023). A review of skin immune processes in acne. Front Immunol, 14, 1324930 .

  5. Lee WJ, Shim WS (2021). Cutaneous Neuroimmune Interactions of TSLP and TRPV4 Play Pivotal Roles in Dry Skin-Induced Pruritus. Front Immunol, 12, 772941 .

  6. Liu YJ (2009). TSLP in epithelial cell and dendritic cell cross talk. Adv Immunol, 101, 1-25 .

  7. Ogulur I, Mitamura Y, Yazici D, et al. (2025). Type 2 immunity in allergic diseases. Cell Mol Immunol, 22(3), 211-242 .

  8. Sano Y, Masuda K, Tamagawa-Mineoka R, et al. (2013). Thymic stromal lymphopoietin expression is increased in the horny layer of patients with atopic dermatitis. Clin Exp Immunol, 171(3), 330-7 .

  9. Wang SH, Zuo YG (2021). Thymic Stromal Lymphopoietin in Cutaneous Immune-Mediated Diseases. Front Immunol, 12, 698522 .

  10. Xiao T, Sun M, Zhao C, et al. (2023). TRPV1: A promising therapeutic target for skin aging and inflammatory skin diseases. Front Pharmacol, 14, 1037925 .

  11. Zeyneloglu C, Bicer C, Akdis CA (2026). High Serum Thymic Stromal Lymphopoietin (TSLP) Levels Link Epithelial Barrier Dysfunction With Local and Systemic Inflammation. Allergy, 81(2), 323-325 .

  12. Ziegler SF (2021). Thymic stromal lymphopoietin, skin barrier dysfunction, and the atopic march. Ann Allergy Asthma Immunol, 127(3), 306-311 .

Also Known As

  • thymic stroma-derived lymphopoietin
  • TSLP